Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β‐catenin signalling to restore tamoxifen sensitivity

Tamoxifen is a first‐line drug for hormone therapy (HT) in oestrogen receptor‐positive breast cancer patients. However, 20% to 30% of those patients are resistant to tamoxifen treatment. Cancer stem cells (CSCs) have been implicated as one of the mechanisms responsible for tamoxifen resistance. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pingping, Feng, Chen, Chen, He, Jiang, Yina, Cao, Fang, Liu, Jie, Liu, Peijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010813/
https://www.ncbi.nlm.nih.gov/pubmed/29602199
http://dx.doi.org/10.1111/jcmm.13619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010813/
https://www.ncbi.nlm.nih.gov/pubmed/29602199
http://dx.doi.org/10.1111/jcmm.13619

Ejemplares similares